Deltex Medical Group Plc (LON:DEMG) Chief Executive Ewan Philips talks to DirectorsTalk about the launch of TruFlow the new, wider beam, single patient disposable probe, it’s improvements encouraging sales and reducing dedicated trainers.
Deltex Medical Group plc manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay. The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
